October 20, 2025

FDA Okays First Oral GLP-1 for CV Risk

Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.

Conexiant

October 20, 2025

Tezepelumab FDA Approval Expands Use to Nasal Polyps

AstraZeneca and Amgen’s anti-thymic stromal lymphopoietin biologic reduces nasal polyp burden and corticosteroid use in the phase 3 WAYPOINT trial.

Conexiant

October 20, 2025

Which Hair Loss Treatments Truly Deliver Results?

Researchers compare prescription and over-the-counter treatments for male hair loss to determine which best improve hair density.

Conexiant

October 16, 2025

‘Dying Alone’: The Growing Challenge for Seniors

An increasing number of older adults are living and dying alone, highlighting the need for physicians to address end-of-life care for patients without family or caregivers.

KFF Health News

October 16, 2025

New Criteria, New Numbers on Obesity

A Lancet Commission definition integrating BMI with anthropometric measures increased obesity prevalence by ~60% in a major US cohort, identifying previously unrecognized high-risk patients while introducing distinct clinical phenotypes.

Conexiant

October 16, 2025

Depression Risk Rises Among Gabapentin Users

Gabapentin is most strongly associated with depression among women, lower-income patients, and those who sleep fewer than 7 hours per night.

Conexiant

October 15, 2025

Study Describes Patterns in Reported Drug Interactions

Researchers analyze about 177,000 drug interactions to identify key medication safety trends.

Conexiant

October 14, 2025

Which ADHD Subtype Causes Most Harm?

Standardized interviews and scales in a university hospital program detail adult attention-deficit/hyperactivity disorder severity, function, and disability.

Conexiant

October 09, 2025

Is Postoperative AF Changing Anticoagulation Decisions?

Cohort of 198 coronary artery bypass grafting patients monitored for 1 year with insertable cardiac devices found high incidence of new-onset atrial fibrillation but minimal late burden.

Conexiant